Kumaraguru Raja
Stock Analyst at Brookline Capital
(0)
# 4935
Out of 5,331 analysts
19
Total ratings
18.18%
Success rate
-29.15%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
QNCX Quince Therapeutics | Initiates Coverage On: Buy | 9 | 1.06 | 749.06% | 1 | Dec 18, 2024 | |
PALI Palisade Bio | Initiates Coverage On: Buy | 38 | 0.79 | 4710.13% | 1 | Nov 20, 2024 | |
SABS SAB Biotherapeutics | Initiates Coverage On: Buy | 8 | 1.55 | 416.13% | 1 | Jun 7, 2024 | |
FBRX Forte Biosciences | Initiates Coverage On: Buy | 100 | 6.92 | 1345.09% | 2 | May 30, 2024 | |
HEPA Hepion Pharmaceutica... | Downgrades: Hold | n/a | n/a | n/a | 1 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 1 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 150 | 0.65 | 22976.92% | 2 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Buy | 15 | 3.97 | 277.83% | 1 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Buy | 9 | n/a | n/a | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Buy | 21 | 4.35 | 382.76% | 1 | Jan 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Buy | 15 | n/a | n/a | 1 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Buy | 90 | 44.43 | 102.57% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 29 31 | 0.51 | 5978.43% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 3360 | 0.87 | 386106.9% | 1 | Sep 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 320 | n/a | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Buy | 120 | n/a | n/a | 1 | Mar 25, 2021 |